Parkinson’s Biotech Remepy Closes $36M Series A to Push Its Flagship Hybrid Drug Into Phase III
Remepy raises $36M Series A to advance Hybridopa into Phase III trials for Parkinson’s and scale its Hybrid Drug pipeline.
Remepy raises $36M Series A to advance Hybridopa into Phase III trials for Parkinson’s and scale its Hybrid Drug pipeline.
Asian equities surged after US inflation cooled and tech stocks rallied, signaling a potential shift in the global rate outlook.
737 Chrome VPN extensions were caught silently routing user traffic through proxy networks, exposing millions to hidden data risks.
From EV batteries to AI models, Chinese technology is reshaping how Apple, Ford, and other global giants build and compete.
Loan Vision’s new AI tool Luna lets mortgage lenders query financials, automate reports, and surface insights without leaving the platform.
A PBS affiliate risks losing 50TB of irreplaceable media after its cloud storage provider stopped responding entirely.
Israel unveils a sweeping national AI action plan targeting top-five global status, with major investment, talent, and infrastructure commitments.
Pernia’s Pop-Up Shop is targeting an Rs 660 crore IPO by August-end, signaling growing investor appetite for India’s luxury fashion market.
DeepMind’s research-first culture is colliding with Google’s product ambitions, and the fallout is reshaping one of AI’s most storied institutions.
Focused ultrasound is treating neurological conditions without a single incision — and it could reshape medicine as we know it.